Ita Novita Sari, Ying-Gui Yang, Yoseph Toni Wijaya, Nayoung Jun, Sanghyun Lee, Kwang Seock Kim, Jeevisha Bajaj, Vivian G Oehler, Soo-Hyun Kim, Soo-Young Choi, Sa-Hee Park, Dong-Wook Kim, Tannishtha Reya, Jaeseok Han, Hyog Young Kwon
Oncogene 2021 JanPolyamines are critical elements in mammals, but it remains unknown whether adenosyl methionine decarboxylase (AMD1), a rate-limiting enzyme in polyamine synthesis, is required for myeloid leukemia. Here, we found that leukemic stem cells (LSCs) were highly differentiated, and leukemia progression was severely impaired in the absence of AMD1 in vivo. AMD1 was highly upregulated as chronic myeloid leukemia (CML) progressed from the chronic phase to the blast crisis phase, and was associated with the poor prognosis of CML patients. In addition, the pharmacological inhibition of AMD1 by AO476 treatment resulted in a robust reduction of the progression of leukemic cells both in vitro and in vivo. Mechanistically, AMD1 depletion induced loss of mitochondrial membrane potential and accumulation of reactive oxygen species (ROS), resulting in the differentiation of LSCs via oxidative stress and aberrant activation of unfolded protein response (UPR) pathway, which was partially rescued by the addition of polyamine. These results indicate that AMD1 is an essential element in the progression of myeloid leukemia and could be an attractive target for the treatment of the disease.
Ita Novita Sari, Ying-Gui Yang, Yoseph Toni Wijaya, Nayoung Jun, Sanghyun Lee, Kwang Seock Kim, Jeevisha Bajaj, Vivian G Oehler, Soo-Hyun Kim, Soo-Young Choi, Sa-Hee Park, Dong-Wook Kim, Tannishtha Reya, Jaeseok Han, Hyog Young Kwon. AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth. Oncogene. 2021 Jan;40(3):603-617
PMID: 33203990
View Full Text